Trial Profile
Prevention of Cytomegalovirus disease in liver transplant patients: studies of antiviral prophylaxis and pre-emptive therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Therapeutic Use
- 16 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
- 11 Aug 2011 New trial record